Evaluation of the efficacy, tolerability and safety of multiple dose intravenous iron sucrose v/s intravenous ferric carboxymaltose in iron deficiency anaemia in postnatal women

2019 ◽  
Vol 12 (2) ◽  
pp. 57-59
Author(s):  
Hemlata Jharbade ◽  
Keyword(s):  
Iron Deficiency ◽  
Multiple Dose ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Ferric Carboxymaltose ◽  
Deficiency Anaemia ◽  
Postnatal Women

scholarly journals Study of effectiveness, tolerability and safety of intravenous iron sucrose in iron deficiency anaemia in postnatal women

2018 ◽  
Vol 7 (11) ◽  
pp. 4366
Author(s):  
R. Niranjana ◽  
K. S. Raja Rajeswari
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Binding Capacity ◽  
Intravenous Iron ◽  
Total Iron ◽  
Iron Sucrose ◽  
Deficiency Anaemia ◽  
Postnatal Women ◽  
The Mean ◽  
Iron Binding Capacity

Background: Iron deficiency anaemia is the most common type of reversible anemia encountered during pregnancy and postpartum period. The present study was done with the objective to find out the efficacy and safety of intravenous iron sucrose in the treatment of iron deficiency anaemia in the postpartum period.Methods: Fifty (50) postnatal patients both after vaginal and caesarean section with iron deficiency anaemia within the first 48 hours with haemoglobin percentage between 6 g/dl and 8g/dl were studied prospectively at the Institute of Obstetrics and Gynaecology, Madras Medical College, Chennai. The patients were given 100 mg of elemental iron diluted in 100 ml of 0.9% normal saline and infused over 15 minutes every alternate day (not more than 3 days in a week) until the required dosage is infused. The blood samples of all the patients were collected and analyzed for haemoglobin (g/dl), hematocrit, mean corpuscular volume (MCV), serum iron, total iron binding capacity (TIBC) and compared before and after therapy.Results: The mean age group of the patients was 24.94 years. Majority of the patients were multipara (68%) and belongs to the class V socio economic status (84%). All the blood parameters were increased significantly (p=0.000) when compared from baseline values to end of the treatment. Mean raise in haemoglobin% after 30 days of treatment was 3.60. Average raise in the mean hematocrit was 8.73. The mean difference in the mean corpuscular volume, total iron binding capacity and the percent saturation was 129.77, 13.55, was 22.26 respectively.Conclusions: Our data confirm that the intravenous iron sucrose was very effective, well tolerated and safe than other forms of iron preparations for treating iron deficiency anaemia in postnatal women.

scholarly journals A comparative study of efficacy, safety and compliance of intravenous ferric carboxymaltose versus iron sucrose in the treatment of iron deficiency anaemia of pregnancy

2021 ◽  
Vol 8 (4) ◽  
pp. 448-453
Author(s):  
Vathsala Kamath ◽  
Naimisha Reddy ◽  
Nishita Shettian
Keyword(s):  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Post Treatment ◽  
Oral Iron ◽  
Iron Sucrose ◽  
Ferric Carboxymaltose ◽  
Third Trimester ◽  
Deficiency Anaemia

Iron deficiency is the most common cause of anaemia worldwide and is associated with significant maternal and fetal morbidity. Current options for treatment include oral iron supplementation which can be ineffective and poorly tolerated, intravenous iron which can be used in patients who are intolerant to or unresponsive to oral iron and red blood cell transfusions which carry an inherent risk because of which it should be avoided. Intravenous iron therapy may reduce the requirement for allogenic blood transfusion. Ferric carboxymaltose is a new intravenous iron formulation promising to be more effective and as safe as iron sucrose. It may even have a better compliance as it offers the administration of a much higher iron dosage at a time.The study was designed to compare the efficacy and safety of IV ferric carboxymaltose versus iron sucrose in the treatment of iron deficiency anaemia of pregnant women with moderate anaemia in the second and third trimester.A hospital based randomized prospective study was done from July 2013 to June 2015 in the department of Obstetrics and Gynaecology, A.J. Institute of Medical Sciences, Mangalore. Baseline haemoglobin, peripheral smear and serum ferritin levels were measured to diagnose iron deficiency anaemia. 60 pregnant women who met the inclusion criteria and who formed the study subjects were randomly allocated into two groups comprising of 30 in Group C (Received ferric carboxymaltose) and 30 in Group S (Received iron sucrose). Outcome was assessed by measuring haemoglobin 3 weeks after treatment and a comparison of the safety and efficacy between the two groups was made. In the present study the commonest age group was 21 to 30 years: 80% in group C and 73.3% in group S and mean age of the study population in group C and S was comparable (25.2±3.54 vs 24.8±4.58 years). The socio demographic characteristics, obstetric history, vitals and pretreatment haemoglobin were comparable in both the groups (p>0.050). The post treatment haemoglobin levels in 63.3% of the women in group C compared to 46.7% in group S were found to be 11 or more and mean post treatment haemoglobin levels were comparable in group C and group S (11.016±0.789 vs 10.73±0.821 gm%; p=0.174). In the present study, post treatment mean increase in haemoglobin levels was noted between 2.0 to 2.5 gm% in 43.3% of the women in group C compared to 50.0% in group S. Ferric carboxymaltose administration in pregnant women in the second and third trimesters is well tolerated and is not associated with any clinical safety concerns. Both ferric carboxymaltose and iron sucrose have a comparable safety profile even when ferric carboxymaltose was administered in a much higher dosage compared to iron sucrose. Ferric carboxymaltose should be considered as the drug of choice, if i.v. iron treatment becomes necessary in the second or third trimester of pregnancy.

Comparative study of efficacy of intravenous iron sucrose versus ferric carboxymaltose in the treatment of iron deficiency anaemia

2020 ◽  
Vol 4 (02) ◽  
pp. 39-43
Author(s):  
Huque Mahfuz ◽  
Mohammad Elias Hossain ◽  
Mohammed Mosleh Uddin ◽  
Mostafil Karim
Keyword(s):  
Iron Deficiency ◽  
Normal Saline ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Iron Therapy ◽  
Ferric Carboxymaltose ◽  
Deficiency Anaemia ◽  
Parenteral Iron ◽  
The Mean

Background: Iron deficiency anaemia (IDA) is a common haematological complication with potentially serious clinical consequences that may require intravenous iron therapy. Parenteral iron therapy results faster and higher replenishment of iron stores and correction of Haemoglobin (Hb) levels with better compliance. The study was to compare the efficacy of intravenous ferric carboxymaltose with intravenous iron sucrose to treat iron deficiency anaemia. Methods: 188 patients were included in the study. 100 patients were given iron sucrose. After a 25 mg test dose on the first infusion only, this was given at a dose of 300 mg by intravenous infusion diluted in 100 ml of normal saline, every alternate day. 88 patients were treated with ferric carboxymaltose at a dose of 500 mg diluted in 100 ml of normal saline by intravenous infusion. Hb level and serum Ferritin of both groups were done before iron therapy and 3 weeks after iron therapy. Results: The mean±SD rise of haemoglobin concentration 3 weeks after iron therapy in iron sucrose group was 11.0±0.61 g/dL, while in ferric carboxymaltose group was 11.2±0.64 g/dL. The mean±SD ferritin 3 weeks after iron therapy in iron sucrose group was 76.0±14.28 ng/mL, while in ferric carboxymaltose group was 80.0±15.16 ng/mL. No serious adverse events were reported in either the ferric carboxymaltose group or iron sucrose group. Conclusions: Ferric carboxymaltose causes higher rise in Hb level as compared to parenteral iron sucrose.

scholarly journals Study of outcome of the treatment with intravenous iron sucrose in moderately anaemic pregnant women

2019 ◽  
Vol 8 (9) ◽  
pp. 3480
Author(s):  
Kohila Kalimuthu ◽  
Vanusha Avudaithangam
Keyword(s):  
Standard Deviation ◽  
Iron Deficiency ◽  
Pregnant Women ◽  
Iron Deficiency Anaemia ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
P Value ◽  
Deficiency Anaemia ◽  
The Mean ◽  
The Difference

Background: Moderate anaemia seen in about 15-20% of pregnant women. Iron sucrose complex which is used intravenously for the correction of Iron deficiency anaemia. The drug has been able to raise the haemoglobin to satisfactory level when used in moderately anaemic iron deficient pregnant women. The objective of this study was to study the improvement of Hb% after treatment with intravenous Iron sucrose complex in moderately anaemic pregnant women belonging to 24-32 weeks of gestational age.Methods: 50 antenatal patients between gestational age 24-32 weeks with hemoglobin between 8-9.5g/dl were selected and included in this study. They were subjected to blood hemoglobin estimation, hematocrit and peripheral smear study. In each infusion, the maximum total dose administered was 200 mg iron sucrose in 100 ml of normal saline, slow IV infused over 30 minutes. Monitoring was done throughout the infusion to observe for any side effects.Results: Mean hemoglobin among the 50 patients before starting the therapy was 8.172g/dl and the mean hemoglobin at the end of one month of completing the therapy was 11.066g/dl. The rise in mean hemoglobin i.e. the difference in the mean hemoglobin before and after treatment was 2.894g/dl. The p value is 0.0001 which is statistically significant. The mean hematocrit of the 50 patients studied before starting the treatment was 26.772% with a standard deviation of 1.914. The mean hematocrit after completing the therapy was 33.872% with a standard deviation of 1.321. The difference in the mean hematocrit was 7.100% with a p value of 0.0001 which is statistically significant.Conclusions: Intravenous iron sucrose complex is well tolerated and highly efficacious in improving hemoglobin, hematocrit in the treatment of iron deficiency anaemia in antenatal women.

scholarly journals Evaluation of safety and efficacy of intravenous iron sucrose therapy for moderate anaemia in antenatal women

2019 ◽  
Vol 8 (10) ◽  
pp. 2258
Author(s):  
K. P. Poojitha ◽  
B. S. B. Mallika ◽  
K. V. Siva Prasad
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anaemia ◽  
Haemoglobin Concentration ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Efficacy And Safety ◽  
Deficiency Anaemia ◽  
Anaemia In Pregnancy ◽  
Moderate Anaemia ◽  
In Pregnancy

Background: Prevalence of iron deficiency anaemia is high in developing countries like India. Treatment of iron deficiency anaemia in pregnancy is very important to bring down maternal mortality rate as blood loss during delivery can lead to death of the patient. The aim and objective of our study is to evaluate the efficacy and safety of intravenous iron sucrose infusions in antenatal women admitted in hospital suffering from moderate iron deficiency anaemia. Special emphasis was given to observe adverse drug effects.Methods: This was a prospective observational study conducted in Obstetrics and Gynaecology department, Government General Hospital, Rangaraya Medical College, Kakinada, Andhra Pradesh. Study period was two months and study population included antenatal women with gestational age less than 37 weeks with moderate iron deficiency anaemia. Peripheral smear was examined for microcytic hypochromic anaemia and they were treated with intravenous infusion of iron sucrose. Haemoglobin levels were checked before and 5 weeks after iron infusions. Monitoring was done for adverse reactions.Results: Out of 322 admissions, 95% were found to be anaemic. 72 patients were suffering from moderate anaemia from which 25 have been included and treated with intravenous iron sucrose infusions. They were observed for efficacy and safety parameters. Two minor adverse events were reported (fever with chills and angioedema of lips) and they were excluded from study. Mean haemoglobin concentration was found to be raised from 7.08±0.73 (SD) to 11.33±0.48 (SD) within 5 weeks for 23 patients.Conclusions: Iron sucrose infusion is safe and effective for anaemia in pregnancy.

Sign in / Sign up

Export Citation Format

Share Document